Search

everythinglearnresearchcommunity

for

Search:↓

The conversation is about the potential cost of GT20029 if FDA approved, with estimates around $150/month. Comparisons are made between GT20029, finasteride, and their mechanisms and side effects.

A South Korean company, Therazyne, has developed a promising hair loss treatment using a WNT chain surrogate that binds to Frizzled 7, with human follicle testing expected soon. Current treatments like minoxidil and finasteride are not seen as cures, and while optimism exists for future solutions like PP405, approval processes are lengthy.

A Spanish dermatologist suggests sulforaphane for androgenetic alopecia (AGA) due to its potential to remove DHT metabolites, though high dosages are needed. A topical formulation might be possible.

User shared 3-week progress using Pyrilutamide once a day for hair loss. Another user shared their 3-month progress with 0.25% concentration Pyrilutamide, experiencing rollback of 4 years in 3 months.

A 48-year-old man's 11-month progress using 1mg finasteride for hair loss treatment, with significant improvement and no side effects. Other users share their experiences, with some also seeing positive results, while others have not been as successful.

Finasteride may affect liver function and cortisol levels, potentially linking it to non-alcoholic fatty liver disease (NAFLD). More research is needed to understand this connection fully.

HMI-115, a potential treatment for hair loss that can reverse miniaturization and make individual hairs thicker, as evidenced by data from macaques given the treatment and one subject in the phase I trial.

PP405 is discussed as a potential hair loss treatment, but its effectiveness and safety are uncertain. Some users express skepticism, while others are hopeful, comparing it to existing treatments like Minoxidil and Finasteride.

The conversation is about updates on Scube3 related to hair loss. Specific treatments mentioned are Minoxidil, Finasteride, and RU58841.

The conversation discusses hair loss treatments, with the original poster considering joining a clinical trial for setipiprant after experiencing side effects from finasteride and disinterest in minoxidil. Some users express skepticism about setipiprant's effectiveness, while others encourage participation in the trial for potential benefits.

A user noticed hair thinning and was prescribed spironolactone, which led to increased hair loss. They were advised to switch to finasteride.

A potential baldness cure, possibly PP405, might be available before the release of GTA 6, which is delayed to 2026 or 2027. There is skepticism about the effectiveness and release timeline of PP405.

PP405 is not commercially available or legitimate in Europe. Users are discussing the lack of availability of this product.

A 24-year-old woman being diagnosed with androgenic alopecia (AGA) who is scared and confused about her hair loss, and the treatment options of Minoxidil, finasteride, RU58841, spironolactone, and possibly a biopsy.

Hair loss is mainly influenced by genetics and DHT sensitivity. Treatments discussed include minoxidil, oral minoxidil, and finasteride.

L-arginine may worsen hair loss by potentially increasing testosterone levels, especially in those with a DHT-sensitive gene. Users discuss the effects of increased nitric oxide on hair loss and consider stopping supplements like zinc and l-arginine to see if hair conditions improve.

A user shared progress pictures using 5mg oral minoxidil and 100mg spironolactone, noting increased body hair and faster nail growth. Another user humorously suggested a new sub for people with similar experiences.

Hair loss discussion includes treatments Minoxidil, Finasteride, and RU58841. Update on HMI-115 clinical trial expected in July or August.

The conversation is about testing the effectiveness of RU58841 for hair loss, with the user planning to increase their dose to 30 mg per day along with 20 mg of Minoxidil. The test results showed approximately 70 mg/ml, which the user considers a good result.

The conversation discusses various theories of hair loss, including DHT sensitivity and genetic factors, with the user willing to use themselves for research due to having a hair loss gene but different hair loss patterns compared to their brothers. Specific treatments were not mentioned in the provided text.

RU58841 solution developed crystals after refrigeration. Letting it reach room temperature and shaking can dissolve the crystals.

Hair loss discussion includes potential HMI-115 treatment. Topical mucuna pruriens shows good results, blocking prolactin possibly more important than blocking DHT.

A user is seeking a new source for RU58841 in the EU after their previous supplier stopped selling it. They mention considering Anagen, Actifolic, Minoxidilmax, and rudirect, and are using a treatment mixing RU58841 with Stemoxydine and Alfatradiol.

A user is seeking a new source for RU58841 in the EU after their previous supplier stopped selling it. They mention considering Anagen, Actifolic, Minoxidilmax, and rudirect, and are using a treatment mixing RU58841 with Stemoxydine and Alfatradiol.

A user reported positive hair growth using a regimen of oral finasteride, minoxidil, Dr. Pen, keto shampoo, and a Capillus 272 LLLT cap. Other users debated the effectiveness of the LLLT cap, with some attributing the success to the combined treatments rather than the cap alone.

The conversation discusses whether gt20029 could cure complete baldness, mentioning verteporfin as a realistic treatment. Other treatments like Minoxidil, finasteride, and RU58841 are implied to be less promising.

Best 2% Minox brand for mixing with pyrilutamide powder and retinoic acid sought. Advice on specific treatments discussed.

A 24-year-old shared their 6-month hair regrowth progress using 1mg oral finasteride, 1ml 5% minoxidil, and 1% topical finasteride daily, noting initial side effects that subsided. They addressed vitamin D, B12 deficiencies, and thyroid issues, expressing satisfaction with the results and encouraging patience with the treatment.

A phase 3 trial for Breezula (clascoterone solution) to treat male pattern hair loss has been listed, with 726 participants and a completion date of January 2025. Other treatments mentioned include Aneira Pharma's combination of minoxidil and latanoprost, Triple Hair's combination of minoxidil, latanoprost, and finasteride, and a new microneedling and LLLT device called StimuSIL.

A compound called MTP3 from the Monoterpene family was found to be safe and highly effective at treating hair loss by inhibiting the FGF5 gene, but its identity is undisclosed for commercial reasons. No specific treatments like Minoxidil, finasteride, or RU58841 were discussed.